Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (6)

Search Parameters:
Keywords = salusin β

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
11 pages, 631 KiB  
Article
Can Serum Salusin-α and Salusin-β Serve as Biomarkers for Early Atherosclerotic Lesions in Obese Children?
by Anna Medyńska, Joanna Chrzanowska, Monika Seifert and Danuta Zwolińska
Int. J. Mol. Sci. 2025, 26(8), 3549; https://doi.org/10.3390/ijms26083549 - 10 Apr 2025
Viewed by 408
Abstract
Obesity increases the risk of atherosclerosis. Recent studies highlight the role of salusins, bioactive peptides, in its development. This study aimed to determine the risk factors for premature atherosclerosis in obese children based on obesity severity and assess the usefulness of serum salusin-α [...] Read more.
Obesity increases the risk of atherosclerosis. Recent studies highlight the role of salusins, bioactive peptides, in its development. This study aimed to determine the risk factors for premature atherosclerosis in obese children based on obesity severity and assess the usefulness of serum salusin-α and salusin-β as early biomarkers. We examined 125 children with simple obesity, divided into two subgroups by BMI-SDS (I: 2–4, II: >4), and we compared them with 33 healthy-weight peers. Obese children had significantly higher serum salusin-α and salusin-β levels, as well as hsCRP, TG, SBP, DBP, and PWV, compared to controls. Only salusin-α levels increased with obesity severity. Salusin-α correlated with BMI SDS and hsCRP, while salusin-β showed no associations. Our findings suggest that salusin-α could be an early inflammation marker and a predictor of atherosclerosis, pointing to salusin-α, rather than salusin-β, as the earliest marker of atherosclerosis in obese children. Further research is needed to confirm these results. Full article
(This article belongs to the Section Molecular Endocrinology and Metabolism)
Show Figures

Figure 1

13 pages, 271 KiB  
Article
Assessment of Metabolic Syndrome and Kidney and Heart Function in Childhood Cancer Survivors
by Aleksandra Janecka, Joanna Stefanowicz, Anna Owczarzak, Marek Tomaszewski, Tomasz Batko and Ninela Irga-Jaworska
Children 2023, 10(6), 1073; https://doi.org/10.3390/children10061073 - 18 Jun 2023
Cited by 1 | Viewed by 2058
Abstract
Background: The survivors of childhood cancer suffer from a number of long-term side effects. These include atherosclerosis and cardiovascular diseases (CVDs) that develop earlier in adulthood than in the rest of the population. The aim of this study was to identify prognostic factors [...] Read more.
Background: The survivors of childhood cancer suffer from a number of long-term side effects. These include atherosclerosis and cardiovascular diseases (CVDs) that develop earlier in adulthood than in the rest of the population. The aim of this study was to identify prognostic factors of developing atherosclerosis before the development of symptomatic CVD. Methods: A total of 141 children that were 7–18 years old were examined; there were 116 survivors of childhood malignancies (hematopoietic and lymphoproliferative malignancies—52; neuroblastoma—22; Wilms tumor—24; other solid tumors—18) and 25 healthy controls. Anthropometric measurements, blood pressure measurements, ultrasonography of the abdomen, echocardiography, and laboratory tests were performed. Results: There were no significant differences in gender distribution, time from the end of the treatment, weight, BMI, prevalence of central obesity, blood pressure and resistive index of the renal arteries, lipid profile, or glucose and fibrinogen levels. Patients with solid tumors had a significantly lower height and worse renal function. Patients with hematological malignancies significantly presented the lowest shortening fraction of the left ventricle. The salusin β levels were significantly higher in the control group than among the patients. Conclusions: The type and severity of side effects are closely related to the type of neoplasm and the treatment that has been undergone. Careful observation and regular follow-up are necessary. Full article
13 pages, 1847 KiB  
Article
The Clinical Significance of Salusins in Systemic Sclerosis—A Cross-Sectional Study
by Joanna Nowaczyk, Leszek Blicharz, Michał Zawistowski, Mariusz Sikora, Michał Zaremba, Joanna Czuwara and Lidia Rudnicka
Diagnostics 2023, 13(5), 848; https://doi.org/10.3390/diagnostics13050848 - 23 Feb 2023
Cited by 3 | Viewed by 2273
Abstract
Background: Systemic sclerosis (SSc) is a connective tissue disease manifesting with progressive fibrosis of the skin and internal organs. Its pathogenesis is strictly associated with vascular disfunction and damage. Salusin-α and salusin-β, endogenous peptides regulating secretion of pro-inflammatory cytokines and vascular smooth muscle [...] Read more.
Background: Systemic sclerosis (SSc) is a connective tissue disease manifesting with progressive fibrosis of the skin and internal organs. Its pathogenesis is strictly associated with vascular disfunction and damage. Salusin-α and salusin-β, endogenous peptides regulating secretion of pro-inflammatory cytokines and vascular smooth muscle proliferation, may potentially play a role in SSc pathogenesis. Objectives: The aim of this study was to assess the concentration of salusins in sera of patients with SSc and healthy controls and to evaluate correlations between the salusins levels and selected clinical parameters within the study group. Materials and methods: 48 patients with SSc (44 women; mean age, 56.4, standard deviation, 11.4) and 25 adult healthy volunteers (25 women; mean age, 55.2, standard deviation, 11.2) were enrolled. All patients with SSc were treated with vasodilators and twenty-seven of them (56%) also received immunosuppressive therapy. Results: Circulating salusin-α was significantly elevated in patients with SSc in comparison to healthy controls (U = 350.5, p = 0.004). Patients with SSc receiving immunosuppression had higher serum salusin-α concentrations compared with those without immunosuppressive therapy (U = 176.0, p = 0.026). No correlation was observed between salusins concentrations and skin or internal organ involvement parameters. Conclusions: Salusin-α, a bioactive peptide mitigating the endothelial disfunction, was elevated in patients with systemic sclerosis receiving vasodilators and immunosuppressants. Increased salusin-α concertation may be associated with the initiation of atheroprotective processes in patients with SSc managed pharmacologically, which requires verification in future studies. Full article
(This article belongs to the Special Issue Recent Advances in Diagnosis and Management of Systemic Sclerosis)
Show Figures

Figure 1

13 pages, 1003 KiB  
Review
Current Knowledge of Selected Cardiovascular Biomarkers in Pediatrics: Kidney Injury Molecule-1, Salusin-α and -β, Uromodulin, and Adropin
by Mirjam Močnik and Nataša Marčun Varda
Children 2022, 9(1), 102; https://doi.org/10.3390/children9010102 - 13 Jan 2022
Cited by 14 | Viewed by 3189
Abstract
Cardiovascular diseases are the leading cause of morbidity and mortality in the modern world. Their common denominator is atherosclerosis, a process beginning in childhood. In pediatrics, the aim of preventive measures is to recognize children and adolescents at risk for accelerated atherosclerosis and [...] Read more.
Cardiovascular diseases are the leading cause of morbidity and mortality in the modern world. Their common denominator is atherosclerosis, a process beginning in childhood. In pediatrics, the aim of preventive measures is to recognize children and adolescents at risk for accelerated atherosclerosis and possible premature cardiovascular events in adulthood. Several diagnostic procedures and biomarkers are available for cardiovascular risk assessment in adults. However, reliable markers in pediatrics are still insufficiently studied. In this contribution, we discuss five potential biomarkers of particular interest: kidney injury molecule-1, salusin-α and -β, uromodulin, and adropin. Studies regarding the pediatric population are scarce, but they support the evidence from studies in the adult population. These markers might entail both a prognostic and a therapeutic interest. Full article
(This article belongs to the Special Issue Cardiovascular Disease in Children)
Show Figures

Graphical abstract

14 pages, 32935 KiB  
Article
Salusin-β in Intermediate Dorsal Motor Nucleus of the Vagus Regulates Sympathetic-Parasympathetic Balance and Blood Pressure
by Lu-Lu Wu, Jin-Hua Bo, Fen Zheng, Feng Zhang, Qi Chen, Yue-Hua Li, Yu-Ming Kang and Guo-Qing Zhu
Biomedicines 2021, 9(9), 1118; https://doi.org/10.3390/biomedicines9091118 - 31 Aug 2021
Cited by 9 | Viewed by 3168
Abstract
The dorsal motor nucleus of the vagus (DMV) is known to control vagal activity. It is unknown whether the DMV regulates sympathetic activity and whether salusin-β in the DMV contributes to autonomic nervous activity. We investigated the roles of salusin-β in DMV in [...] Read more.
The dorsal motor nucleus of the vagus (DMV) is known to control vagal activity. It is unknown whether the DMV regulates sympathetic activity and whether salusin-β in the DMV contributes to autonomic nervous activity. We investigated the roles of salusin-β in DMV in regulating sympathetic-parasympathetic balance and its underline mechanisms. Microinjections were carried out in the DMV and hypothalamic paraventricular nucleus (PVN) in male adult anesthetized rats. Renal sympathetic nerve activity (RSNA), blood pressure and heart rate were recorded. Immunohistochemistry for salusin-β and reactive oxidative species (ROS) production in the DMV were examined. Salusin-β was expressed in the intermediate DMV (iDMV). Salusin-β in the iDMV not only inhibited RSNA but also enhanced vagal activity and thereby reduced blood pressure and heart rate. The roles of salusin-β in causing vagal activation were mediated by NAD(P)H oxidase-dependent superoxide anion production in the iDMV. The roles of salusin-β in inhibiting RSNA were mediated by not only the NAD(P)H oxidase-originated superoxide anion production in the iDMV but also the γ-aminobutyric acid (GABA)A receptor activation in PVN. Moreover, endogenous salusin-β and ROS production in the iDMV play a tonic role in inhibiting RSNA. These results indicate that salusin-β in the iDMV inhibits sympathetic activity and enhances vagal activity, and thereby reduces blood pressure and heart rate, which are mediated by NAD(P)H oxidase-dependent ROS production in the iDMV. Moreover, GABAA receptor in the PVN mediates the effect of salusin-β on sympathetic inhibition. Endogenous salusin-β and ROS production in the iDMV play a tonic role in inhibiting sympathetic activity. Full article
(This article belongs to the Special Issue Neuropeptides in Biomedicines)
Show Figures

Figure 1

12 pages, 294 KiB  
Review
Endogenous Bioactive Peptides as Potential Biomarkers for Atherosclerotic Coronary Heart Disease
by Takuya Watanabe, Kengo Sato, Fumiko Itoh, Kohei Wakabayashi, Masayoshi Shichiri and Tsutomu Hirano
Sensors 2012, 12(4), 4974-4985; https://doi.org/10.3390/s120404974 - 18 Apr 2012
Cited by 23 | Viewed by 8309
Abstract
Cardiovascular disease is the leading cause of death worldwide, with high medical costs and rates of disability. It is therefore important to evaluate the use of cardiovascular biomarkers in the early diagnosis of coronary artery disease (CAD). We have screened a variety of [...] Read more.
Cardiovascular disease is the leading cause of death worldwide, with high medical costs and rates of disability. It is therefore important to evaluate the use of cardiovascular biomarkers in the early diagnosis of coronary artery disease (CAD). We have screened a variety of recently identified bioactive peptides candidates in anticipation that they would allow detection of atherosclerotic CAD. Especially, we have focused on novel anti-atherogenic peptides as indicators and negative risk factors for CAD. In vitro, in vivo and clinical studies indicated that human adiponectin, heregulin-β1, glucagon-like peptide-1 (GLP-1), and salusin-α, peptides of 244, 71, 30, and 28 amino acids, respectively, attenuate the development and progression of atherosclerotic lesions by suppressing macrophage foam cell formation via down-regulation of acyl-coenzyme A: cholesterol acyltransferase-1. Circulating levels of these peptides in the blood are significantly decreased in patients with CAD compared to patients without CAD. Receiver operating characteristic analyses showed that salusin-α is a more useful biomarker, with better sensitivity and specificity, compared with the others for detecting CAD. Therefore, salusin-α, heregulin-β1, adiponectin, and/or GLP-1, alone or in various combinations, may be useful as biomarkers for atherosclerotic CAD. Full article
(This article belongs to the Special Issue Biomarkers and Nanosensors: New Approaches for Biology and Medicine)
Show Figures

Back to TopTop